(VIANEWS) – Bionano Genomics (NASDAQ: BNGO) shares surged 14.33% to EUR1.72 at 22:22 EST Thursday evening, continuing their upward momentum over two trading sessions and well above their 52-week low of EUR1.50. Meanwhile, the NASDAQ Composite Index increased 0.35% to EUR14,784.95 today after five straight gains – evidence that today’s trading session appears to be heading in an upward direction.
About Bionano Genomics
Bionano Genomics is a genome analysis software and services company founded in 2003 that offers solutions for genomics labs to analyze and interpret their data. Their flagship product, Saphyr, offers sample-to-result structural variation analysis by optical genome mapping that facilitates genome analysis as well as understanding genetic variation and function. Furthermore, Bionano Genomics also provides software, reagents, protocols for extracting ultrahigh molecular weight DNA extraction as well as testing services identifying the genetic causes for various disorders. Since 2003 they have been operating from San Diego California.
Yearly Analysis
Bionano Genomics stock has recently seen its price fluctuate between EUR22.90 and EUR1.19 over the course of a year, suggesting it experienced significant price drops before recovering recently.
Bionano Genomics is projected to experience strong sales growth of 29.3% this year and 43% next year, which may be driven by its innovative products and services, as well as increasing demand for genome sequencing and analysis services.
Bionano Genomics currently boasts an EBITDA ratio of 0.33, which indicates positive earnings before accounting for interest, taxes, depreciation and amortization expenses. This suggests the company is profitable with strong financial standing.
Overall, Bionano Genomics appears to be an attractive investment opportunity due to its expected sales growth and positive EBITDA performance. As with any investment decision, however, additional research and analysis must be completed in order to fully comprehend both risks and potential rewards associated with it.
Technical Analysis
Bionano Genomics stock price has fallen below both its 50-day and 200-day moving averages, suggesting an incoming downward trend. Nonetheless, its volume appears higher than usual and could indicate increased investor enthusiasm.
Regarding volatility, the stock has experienced negative weekly and monthly volatility averages, while experiencing positive quarterly averages. The highest amplitude of average volatility over the past week, month and quarter has been 3.26% for each time frame – suggesting relatively steady performance over longer time frames but more fluctuation during shorter time frames.
Overall, Bionano Genomics stock price appears to be trending downward, however with higher than average volumes and stable quarterly volatility it could present investors with an opportunity to buy.
Quarter Analysis
Bionano Genomics has experienced strong sales growth for this quarter at 28.3% and estimates 46.5% growth for its next quarterly. Their year-on-year quarterly revenue growth increased 29% year over year to total 33.61M for twelve trailing months indicating strong financial condition and continued performance going forward. Overall, Bionano Genomics seems like a promising investment option within biotechnology.
Equity Analysis
Bionano Genomics’ financial information indicates a trailing 12-month earnings per share (EPS) figure of EUR-7.17; this could signal to potential investors that Bionano Genomics has experienced losses recently and this may cause concern about potential investment returns.
Furthermore, the company’s return on equity (ROE) for the past twelve months stands at negative -113.43% – which indicates that profits are not being generated relative to shareholder equity, potentially raising alarm bells with investors.
Bionano Genomics may not represent an attractive investment opportunity at this time. Potential investors should carefully consider other aspects, such as its growth prospects and competitive standing before making their decision to invest.
More news about Bionano Genomics (BNGO).
